Earnings Call · Q2 FY2025·2025-08-05

Q2 25EPS -45.45%·Rev n/aQ1 25EPS 0.00%·Rev n/aQ4 24EPS +50.00%·Rev n/aQ3 24EPS -14.29%·Rev n/a⚠ consensus missing

Iterum Therapeutics plc ITRMF

Kevin Dalton — Senior Director, Legal Affairs

Corey N. Fishman — Chief Executive Officer

Judith M. Matthews — Chief Financial Officer

−2.7%1d on move date−2.2% vs SPY3d−2.7%5d0.0%

Research tier

Behavioral profile computed for 3 speakers on this call.

Sign in to view the Behavioral Lean, the Behavioral Deviation Score, the speaker decomposition, and the novel forward-guidance phrases flagged on this call — each scored against the speaker's own prior-call baseline.

Behavioral data on every earnings call

Per-speaker language deviation, scored against each executive's own history. Explore more ITRMF calls or request research access.

More ITRMF calls Browse calls Request research access